Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Conditions
- Small Cell Lung Carcinoma
Interventions
- BIOLOGICAL: coformulation pembrolizumab/quavonlimab
- DRUG: lenvatinib
- BIOLOGICAL: MK-4830
- BIOLOGICAL: coformulation favezelimab/pembrolizumab
- BIOLOGICAL: R-DXd
Sponsor
Merck Sharp & Dohme LLC
Collaborators